847
Views
15
CrossRef citations to date
0
Altmetric
Research Paper

Adult immunization with 13-valent pneumococcal vaccine in Campania region, South Italy

An economic evaluation

, , , , , , , , , , , , , , , , & show all
Pages 492-497 | Received 31 Jul 2013, Accepted 20 Oct 2013, Published online: 01 Nov 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Jessica J. P. Shami, Swathi Pathadka, Esther W. Chan, Jennifer Hui, Reiko Sato, Shilpa Patil & Xue Li. (2020) Evaluating the cost-effectiveness of a sequential pneumococcal vaccination compared to single-dose vaccination strategy for adults in Hong Kong. Human Vaccines & Immunotherapeutics 16:8, pages 1937-1944.
Read now
Sara Boccalini, Angela Bechini, Roberto Gasparini, Donatella Panatto, Daniela Amicizia & Paolo Bonanni. (2017) Economic studies applied to vaccines against invasive diseases: An updated budget impact analysis of age-based pneumococcal vaccination strategies in the elderly in Italy. Human Vaccines & Immunotherapeutics 13:2, pages 417-422.
Read now
Barbara Rita Porchia, Paolo Bonanni, Angela Bechini, Gugliemo Bonaccorsi & Sara Boccalini. (2017) Evaluating the costs and benefits of pneumococcal vaccination in adults. Expert Review of Vaccines 16:2, pages 93-107.
Read now
S Dirmesropian, JG Wood, CR MacIntyre & AT Newall. (2015) A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly. Human Vaccines & Immunotherapeutics 11:4, pages 818-825.
Read now

Articles from other publishers (11)

Molly Sauer, Prarthana Vasudevan, Ankita Meghani, Karuna Luthra, Cristina Garcia, Maria Deloria Knoll & Lois Privor-Dumm. (2021) Situational assessment of adult vaccine preventable disease and the potential for immunization advocacy and policy in low- and middle-income countries. Vaccine 39:11, pages 1556-1564.
Crossref
Alessandro Sanduzzi, Angelo Canora, Patrizia Belfiore, Marialuisa Bocchino, Renato Liguori & Giorgio Liguori. (2019) Impact of 13Valent Vaccine for Prevention of Pneumococcal Diseases in Children and Adults at Risk: Possible Scenarios in Campania Region. Infectious Disorders - Drug Targets 19:4, pages 403-408.
Crossref
Marina Treskova, Stefan M. Scholz & Alexander Kuhlmann. (2019) Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions. PharmacoEconomics 37:9, pages 1093-1127.
Crossref
Elizabeth T. Cafiero-Fonseca, Andrew Stawasz, Sydney T. Johnson, Reiko Sato & David E. Bloom. (2017) The full benefits of adult pneumococcal vaccination: A systematic review. PLOS ONE 12:10, pages e0186903.
Crossref
Priscilla Magalhaes Loze, Luciana Bertholim Nasciben, Ana Marli Christovam Sartori, Alexander Itria, Hillegonda Maria Dutilh Novaes & Patrícia Coelho de Soárez. (2017) Vaccines are different: A systematic review of budget impact analyses of vaccines. Vaccine 35:21, pages 2781-2793.
Crossref
Giorgio Liguori, Patrizia Belfiore, Maurizio D’Amora, Renato Liguori & Mario Plebani. (2017) The principles of Health Technology Assessment in laboratory medicine. Clinical Chemistry and Laboratory Medicine (CCLM) 55:1, pages 32-37.
Crossref
Nicola Principi & Susanna Esposito. (2016) Prevention of Community-Acquired Pneumonia with Available Pneumococcal Vaccines. International Journal of Molecular Sciences 18:1, pages 30.
Crossref
Livio Garattini, Anna Padula & Milene Rangel Da Costa. (2015) Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?. PharmacoEconomics 34:3, pages 221-224.
Crossref
Jose Miguel Rodríguez González-Moro, Rosario Menéndez, Magda Campins, Nadia Lwoff, Itziar Oyagüez, María Echave, Javier Rejas & Fernando Antoñanzas. (2015) Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain. Clinical Drug Investigation 36:1, pages 41-53.
Crossref
Greg L. Plosker. (2015) 13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults. Drugs 75:13, pages 1535-1546.
Crossref
Janne A. Martikainen, Erkki J. Soini, Juha Laine, Heidi Åhman, Ville Postila & Peter Klemets. (2014) Economic impact of 13-valent pneumococcal conjugate vaccine in Finnish adults ≥50 years with underlying chronic medical conditions. Journal of Evaluation in Clinical Practice 20:4, pages 333-341.
Crossref